Navigation Links
Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025
Date:10/7/2010

NEW YORK, Oct. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biobanking for Medical R&D: Technology and Market 2010-2025

http://www.reportlinker.com/p0306323/Biobanking-for-Medical-RD-Technology-and-Market-2010-2025.html

Report Details – how will biobanking develop and contribute to healthcare? Our new report explains its prospects

Do you want to know the prospects for biobanking in medical research, pharmaceutical R&D and personalised medicine? Our new study shows you its technological and commercial potential. You can have that report today, staying ahead. Demand for biobanking has been expanding. There will be commercial growth, with important trends to watch from 2010 onwards.

Our report shows how you can benefit. As the pharmaceutical industry shifts towards personalised medicine, there is a need for usable, well-maintained biospecimen collections. We show you where the biobanking sector is heading, forecasting its technological and commercial potential from 2010 onwards.

Biobanking for Medical R&D: Technology and Market 2010-2025 reveals the opportunities and challenges the biobanking sector will face. These include consolidation and harmonisation of biobanking practices. Advances in genetic research, stem cell research and regenerative medicine increase the importance of biobanking, as well as its commercial potential.

Our report provides data on current and future revenue values for the biobanking sector, globally and nationally. You will find that information only there. We cover both the for-profit and non-profit sectors. We analyse strengths, weaknesses and revenue trends for biobanking from 2010 to 2025. You can discover the sector's prospects today.

Biobanked collections are increasingly valued by medical researchers and drug developers worldwide. What are the potential benefits to the pharma industry? How will biobanking product and service providers benefit? Our new report gives you answers and trends, saving you time and aiding your decisions.

Analysis of the world biobanking industry and market to meet your needsOur new report examines the biobanking sector for medical R&D critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses and other data. You will discover market strengths, weaknesses, opportunities and threats. We include over 45 tables and figures and an expert interview, as shown in the lists that follow. This is a market- and industry-centred study, with analyses and opinion to benefit your work.

Why you should buy Biobanking for Medical R&D: Technology and Market 2010-2025Our report gives you the following benefits in particular:

• You will receive hard data for the biobanking sector – and much more – including our revenue predictions from 2010 to 2025

• You will receive analyses for the overall market and its main components

• You will read the first report of its kind, one providing insight into the biobanking industry and market, helping you to stay ahead

• You will find out the potential revenues in leading national markets (US, Germany, France, Italy, Spain, UK, Japan, India and China) from 2010 to 2025

• You will assess leading organisations in biobanking, discovering their activities and prospects

• You will find out where biobanking is heading – technologically and commercially – from 2010 onwards

• You will discover the drivers, restraints, competition and opportunities influencing the biobanking sector

• You will discover expert views from our survey.

With our report, you can assess that emerging sector, aiding your decisions and saving time.You can have this report todayOur new report can benefit everybody interested in healthcare biotechnology. We reveal prospects for biobanking from the present onwards. Do you want to harness those opportunities? You can stay ahead by ordering our report now.

Table of Contents1. Executive Summary

1.1 Summary Points

1.2 Aims, Scope and Format of this Report

1.2.1 Speculative Aspects of Assessing the Biobanking Market

1.2.2 Chapter Outlines

1.3 Research and Analysis Methods

2. Introduction to Biobanking

2.1 Biobanking

2.1.1 Processes Involved in Biobanking

2.2 Biobanks: A Two-fold Character

2.3 Key Features

2.4 Classification of Biobanks

2.4.1 Volunteer Groups

2.4.1.1 Population-based Biobanks

2.4.1.2 Disease-oriented Biobanks

2.4.2 Ownership or Funding Structure

2.5 Guidelines and Standards

2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research

2.5.2 Industry Standards for Biobanks

2.5.3 Biobanking Processes Governed by Guidelines

2.6 Laws and Regulations for Biobank-based Research

3. Biobanking and the Pharmaceutical Industry

3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry

3.1.1 Research and Drug Development

3.1.1.1 Understanding Disease Pathways

3.1.1.2 Drug Discovery

3.1.1.3 Biomarker Discovery

3.1.2 Therapeutics

3.1.3 Clinical Trials

3.2 Biobanks Operated by Pharmaceutical Companies

4. Biobanking: Associated Market (Systems, Software, Consumables, and Services Associated with Biobanking)

4.1 Systems/ Technologies

4.1.1 Automated Liquid Handling

4.1.1.1 Frozen Aliquotting: New Technology in Development

4.1.2 Storage

4.1.2.1 Ultra-low Temperature Freezing

4.1.2.2 Room-Temperature Storage

4.1.3 RFID and Tagging Technologies

4.2 Software

4.2.1 Laboratory Information Management System (LIMS)

4.2.1.1 LIMS Functions

4.3 Consumables

4.4 Services

5. Global Biobanking Market, 2010-2025

5.1 Current State of the Biobanking Market

5.2 Geographical Footprint

5.3 Growing Demand for Biobank Resources

5.4 Revenue Forecast for Total Biobanking Market

5.4.1 Scope and Limitations

5.4.2 Biobanking Market, 2010-2025

5.5 Commercial Biobanks: New Resources for Research

6. Human Tissue Banking Market

6.1 Revenue Forecast for Total Human Tissue Banking Market, 2010-2025

6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2010-2025

6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2010-2025

6.4 Commercial Participants in the Human Tissue Banking Market

6.4.1 Business Models of Companies in the Biobanking Market

6.4.2 Tissue Solutions Ltd.

6.4.2.1 Overview

6.4.2.2 Global Presence

6.4.2.3 Products and Services

6.4.2.3.1 Banked Samples

6.4.2.3.2 Prospective Samples

6.4.2.3.3 Fresh Samples

6.4.2.3.4 Freshly Isolated and Primary Cells

6.4.2.3.5 Services

6.4.2.4 Strengths and Capabilities

6.4.2.5 Future Outlook

6.4.3 Asterand Plc.

6.4.3.1 Overview

6.4.3.2 Global Presence

6.4.3.3 Products and Services

6.4.3.3.1 XpressBANK

6.4.3.3.2 ProCURE

6.4.3.3.3 PhaseZERO

6.4.3.3.4 BioMAP

6.4.3.4 Asterand: Providing Barriers for New Market Entrants?

6.4.3.5 Financial Performance

6.4.3.6 Future Outlook

7. Stem Cell Banking

7.1 Overview

7.2 Revenue Forecast for Total Stem Cell Banking, 2010-2025

7.3 Stem Cell Banks for Research: High Growth Possible

7.4 Umbilical Cord Blood Banking for Stem Cells

7.4.1 Biological Insurance: Private Blood Banking

7.4.2 Umbilical Cord Banking: The Controversies

7.4.2.1 US Oversight of Cord Blood Stem Cells

7.4.3 Companies in the Field

7.4.3.1 Cord Blood America: Looking Towards the Chinese Market

7.4.3.2 ViaCord: 145,000 Blood Units in Storage

7.4.3.3 Cryo-Cell International: The First Cord Blood Bank

7.4.3.4 Stem Cell Authority: Exclusive Stem Cells

7.4.3.5 LifebankUSA: Placenta-Cord Banking

7.5 Gene/ DNA Banking

8. Industry Trends

8.1 Automated Biobanking

8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking

8.1.2 Addressing Sample Storage and Tracking Issues

8.2 Green Banking

8.3 Creation of National Biobanks

8.4 HIPAA Amendments

9. SWOT Analysis of the Biobanking Sector

9.1 Strengths

9.1.1 Wealth of Information for Genetic Research

9.1.2 Potential to Change Treatments

9.1.3 Many Governments Support Biobanking

9.2 Weaknesses

9.2.1 Quality Concerns for Existing Biospecimen Collections

9.2.2 Lack of Standardisation and Harmonisation of Best Practices

9.2.3 Limited Sharing and Linkage of Biobanks

9.3 Opportunities

9.3.1 Genome-Wide Association Studies (GWAS)

9.3.2 Personalised Medicine

9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach

9.4 Threats

9.4.1 Ethical and Regulatory Issues

9.4.1.1 Limitations of Informed Consent in Biobanking

9.4.1.2 Confidentiality and Security to Prevent Improper Use

9.4.2 Social and Cultural Issues

9.4.3 Ownership Issues

9.4.4 Funding

10. Expert Opinion

10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions

10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry

10.1.2 On Commercial Aspects of Biobanking

10.1.3 On the Business of Tissue Solutions

10.1.4 On the Attractiveness of Human Tissue Banking

10.1.5 On the Future of the Biobanking Market

11. Conclusions

11.1 Biobanking for Research and Therapeutics

11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine?

11.3 Commercial Drivers of the Biobanking Market

11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth

List of Tables

Table 2.1 Prominent Population-based Biobanks, 2010

Table 2.2 Prominent Disease-oriented Biobanks, 2010

Table 2.3 Some Guidelines and Recommendations for Biobanks, 2010

Table 2.4 Laws and Regulations for Biobank-based Research, Consent Requirements, and Privacy/ Data Protection, 2010

Table 3.1 Some Pharmaceutical and Biotechnology Companies with In-house Biobanks, 2010

Table 4.1 Prominent Companies in the Automated Liquid Handling Market, 2010

Table 4.2 Prominent Companies in Ultra-low Temperature Freezer Market, 2010

Table 4.3 Prominent LIMS Vendors, 2010

Table 4.4 Prominent Consumables Suppliers for Biobanking, 2010

Table 4.5 Prominent Biorepository Service Providers, 2010

Table 5.1 Estimated Number of Biobanks in Europe, 2010

Table 5.2 Overall Biobanking Market: Revenue Forecast, 2010-2017

Table 5.3 Overall Biobanking Market: Revenue Forecast, 2018-2025

Table 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2017

Table 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2018-2025

Table 6.3 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2010-2017

Table 6.4 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2018-2025

Table 6.5 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2010-2025

Table 6.6 Leading Companies in the World Biobanking Market, 2010

Table 6.7 Asterand: Revenue by Segment, 2008 and 2009

Table 6.8 Asterand: Revenue by Geographical Area, 2008 and 2009

Table 7.1 Stem Cell Banking: Revenue Forecast, 2010-2017

Table 7.2 Stem Cell Banking: Revenue Forecast, 2018-2025

Table 7.3 Prominent Stem Cell Banks Serving the Research Community, 2010

Table 7.4 Prominent Companies in the Cord Blood Banking Market, 2010

Table 9.1 SWOT Analysis of the Biobanking Sector, 2010

Table 9.2 Information for a Biobank Donor, 2010

List of Figures

Figure 2.1 Processes Involved in Biobanking, 2010

Figure 2.2 Classification of Biobanks, 2010

Figure 3.1 Biobanking and Pharmaceutical Development, 2010

Figure 4.1 Biobanking Industry: Value Chain Model, 2010

Figure 4.2 Functions of LIMS, 2010

Figure 5.1 Overall Biobanking Market: Revenue Forecast, 2010-2025

Figure 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2025

Figure 6.2 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2010-2025

Figure 6.3 Human Tissue Banking: Market Shares by Type of Biobank, 2010

Figure 6.4 Human Tissue Banking: Market Shares by Type of Biobank, 2025

Figure 6.5 Human Tissue Banking: Market Shares for Leading National Markets, 2010

Figure 6.6 Human Tissue Banking: Market Shares for Leading National Markets, 2015

Figure 6.7 Human Tissue Banking: Market Shares for Leading National Markets, 2020

Figure 6.8 Human Tissue Banking: Market Shares for Leading National Markets, 2025

Figure 6.9 Commercial Sourcing of Biological Samples, 2010

Figure 6.10 Commercial Banking of Biological Samples, 2010

Figure 6.11 Asterand: Revenues, 2008 and 2009

Figure 6.12 Asterand: Revenue Shares by Region of Destination, 2009

Figure 6.13 Asterand: Revenue Shares by Region of Origin, 2009

Figure 7.1 Stem Cell Banking: Revenue Forecast, 2010-2025

Companies Listed

Abcellute

Abgene

Adnexus Therapeutics

AFNOR Groupe

AKH Biobank

AlloSource

American National Bioethics Advisory Commission

American Type Culture Collection

Amgen

Analytical Biological Services

ARCH Venture Partners

Asterand

Asterand UK Limited

Asterand

AstraZeneca

Australasian Biospecimen Network (ABN)

Autoscribe

AXM Pharma

Bayer-Schering

Beckman Coulter

Biobank Ireland Trust

Biobank Japan

Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)

BioFortis

Biogen Idec

BioLife Solutions

Biomatrica

Biopta

BioRep

BioSeek

BioServe

BioStorage LLC

BioStorage Technologies

BrainNet Europe

Caliper LifeSciences

Canadian Partnership for Tomorrow

CARTaGENE

Cellgene Corporation

Cells4Health

Chemagen

CLB/ Amsterdam Medical Center

CorCell

Cord Blood America

Cord Blood Registry

CordLife

Cordon Vital (CBR)

Coriell Institute for Medical Research

Council of Europe (CoE)

Covance

Cryo Bio System

Cryo-Cell International

Cryometrix

Cryo-Save

Cureline

Cybrdi

Danubian Biobank Foundation

deCODE Genetics

Department of Health (DoH)

Department of Transportation (DOT)

Draper Laboratory

EGeen

Eli Lilly

Eolas Biosciences

Estonian Genome Project

EuroBioBank

European Commission (EC)

European Health Risk Monitoring (EHRM)

European Medicines Agency (EMA/EMEA)

European Union Group on Ethics (EGE)

Fisher BioServices

Fondazione I.R.C.C.S. Istituto Neurologico C. Besta

Food and Drug Administration (US FDA)

Foundation for the National Institutes of Health

Fundacion Istituto Valenciano de Oncologia

Fundeni Clinical Institute

Genentech

Generation Scotland

GeneSaver

GeneSys

Genetic Association Information Network (GAIN)

Genizon Biosciences

Genome Quebec Biobank

GenomEUtwin

Genomic Studies of Latvian Population

GenVault

German Dementia Competence Network

GlaxoSmithKline (GSK)

H. Lee Moffitt Cancer Center and Research Institute

Hamilton

Hopital Necker Paris – Necker DNA Bank

Human Tissue Authority (HTA)

Hungarian Biobank

HUNT, Norway

ILSBio LLC

Inbiobank

Indivumed

INMEGEN

Institut National de la Sante et de la Recherche Medicale (INSERM)

Integrated BioBank of Luxembourg

International Agency for Research on Cancer (IARC)

International Air Transport Association (IATA)

International Organization for Standardization (ISO)

International Society for Biological and Environmental Repositories (ISBER)

International Stem Cell Corporation

Kaiser Permanente

KORA-gen

LabVantage Solutions

LabWare

Leiden University Medical Center

LifebankUSA

LifeGene

LifeStem

Malaysian Cohort Project

Matrical Biosciences

Matrix

Medical Research Council (MRC)

Medical University of Gdansk

Merck & Co.

Merck Sharp & Dohme Limited (MSD)

Merck-Serono

Micronic

Milennium (Takeda Oncology Company)

MVE-Chart

National Cancer Institute (NCI)

National DNA Bank (US)

National Human Genome Research Institute (NHGRI)

National Institute of Environmental Health

National Institutes of Health (NIH)

National Public Health Institute

National Research Ethics Service (NRES)

NeoCodex

NeoStem

Neuromuscular Bank of Tissues and DNA Samples

New Brunswick Scientific

NEXUS Biosystems

Northwest Regional Development Agency

Novacare Bio-Logistics

Novartis

NUgene Project

Ocimum Biosolutions

Office of Biorepositories and Biospecimen Research (OBBR)

OnCore UK

Organisation for Economic Co-operation and Development (OECD)

OriGene

Oxagen

Pacific Bio-Material Management

PathServe

Perkin Elmer

Pfizer

Pharmagene Laboratories Trustees Limited

Polaris Ventures

Pop-Gen (University Hospital Schleswig-Holstein)

PrecisionMed

Prevention Genetics

ProMedDx

Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE)

ProteoGenex

Public Population Projects in Genomics (P3G Consortium)

Qiagen

RAND Corporation

REMP

Reproductive Genetics Institute (RGI)

Research Centre of Vascular Diseases, University of Milan

Rhode Island BioBank, Brown University

Roche

RTS Life Science

Saga Investments LLC

Sanofi-Aventis

SANYO Biomedical

Scottish Government

Seattle Genetics

SeqWright DNA Technology Services

SeraCare Life Sciences

Singapore Tissue Network

StarLIMS

Steelgate

Stem Cell Authority

Stem Cells for Safer Medicine (SC4SM)

Stem Cells Research Forum of India

Stemride International

Taiwan Biobank

Taizhou Biobank

TAP

Tecan

The Automation Partnership

The Sorenson Molecular Genealogy Foundation (SMGF)

Thermo Fisher Scientific

Tissue Solutions

Titan Pharmaceuticals

Trinity Biobank

Tumorotheque Necker-Entants Malades

UK Biobank

UK Stem Cell Bank

UmanGenomics

Umea University

University Hospital Angers

University Medical Center Gent

University of Massachusetts Stem Cell Bank

University of Tuebingen, Department of Medical Genetics

US Biomax

Vasterbotten County Council

ViaCord

Wellcome Trust

Wellcome Trust Case-Control Consortium (WTCCC)

Western Australian Genome Health Project

Wheaton Science International

Wisconsin International Stem Cell (WISC) Bank

World Health Organization (WHO)

To order this report:Blood Supply, Tissue Banking and Transplantation Industry: Biobanking for Medical R&D: Technology and Market 2010-2025

Blood Supply, Tissue Banking and Transplantation Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):